A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (V114-021/PNEU-FLU)

NCT03615482 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1200

Enrollment

INDUSTRY

Sponsor class

Conditions

Pneumococcal Infections

Interventions

BIOLOGICAL: V114
BIOLOGICAL: QIV
BIOLOGICAL: Matching Placebo for V114

Sponsor

Merck Sharp & Dohme LLC